The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and ...

Three popular GLP-1 receptor agonists carried similar risks for serious gastrointestinal (GI) events among adults with type 2 ...

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney ...

Patients with T2D and inflammatory arthritis who received GLP-1 RAs vs SGLT2 inhibitors had lower rates of hypoglycemia, serious infections, and AKI.

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

Sean Virani, MD, lead author of the new guidelines and president of the CCS, explained that the guidelines use the term ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective ...

Type 1 diabetes with CKD is understudied with no advancement of therapy options since the 1990s. The FINE-ONE phase 3 trial addresses a high, unmet need for treatments.